Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cytotherapy|February 10, 2025
Higher risk of GVHD but better long-term survival: impact of p-ALG versus r-ATG in high-risk hematological malignancy patients following MSDTLingyan Yan, Linli Lu, Liwen Wang, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|January 14, 2021
Factors influencing development of non-cardiac chest pain after endoscopic submucosal dissection for esophageal neoplasms: a retrospective case-control study of 309 patients from a single centerDian Zhao, Ying Liu, Lei Wang, et al.
Journal of Translational Medicine|November 29, 2024
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myelomaYuhan Yan, Yixuan Tu, Qian Cheng, et al.
Cytotherapy|June 12, 2022
CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphomaQian Cheng, Jingwen Tan, Rui Liu, et al.
Blood|January 2, 2026
Heat stress activates the coagulation cascade through Z-DNA-binding protein 1-dependent necroptosisFanglin Li, Jinxiu Li, Jian Shi, et al.
Molecular Medicine (Cambridge, Mass.)|August 23, 2024
Caspase-11 signaling promotes damage to hippocampal CA3 to enhance cognitive dysfunction in infectionNi Liang, Yi Li, Chuang Yuan, et al.
Human Gene Therapy|February 14, 2022
CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System LymphomaRui Liu, Qian Cheng, Liqing Kang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 26, 2025
Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple MyelomaLiwen Wang, Linzhi Xie, Yi Zhou, et al.
Blood Cancer Journal|March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)Juying Wei, Qingqing Cai, Liling Zhang, et al.
Pageof 2